Dapagliflozin for membranous nephropathy relapse
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if dapagliflozin, a medication used for diabetes and kidney disease, can help control immune activity in people with membranous nephropathy who have had a recent immunological relapse. It aims to see if it can reduce protein in the urine and delay the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 85 years old.
- You must have membranous nephropathy with anti-PLA2R1 antibodies in your blood.
- Your urine protein-to-creatinine ratio (UPCR) must be between 0.5 and 3.5 g/g.
- You must have had an immunological relapse (antibody levels over 14 RU/mL after they had become undetectable) while still having partial or complete clinical remission.
- You must be on a stable, maximum tolerated dose of standard treatments like blood pressure medications and diuretics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This study tests if a once-daily medication called dapagliflozin (Forxiga) can reduce inflammation and improve iron use and red blood cell production in people with both type 2 diabetes and chronic kidney disease. It may help protect your kidneys and overall health.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
Hear when a new Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.